PDF(Pubmed)
Abstract：
OBJECTIVE: Carbohydrate antigen 199 (CA199) is a standard tumor marker, and recent studies have found elevated in CA199 levels in patients with diabetes. However, there is no systematic measurement and comparison of serum CA199 levels in patients with diabetes and cancer. Here, a detailed description of the changes in serum CA199 levels in patients with type 2 diabetes and various cancers was explored.
METHODS: A total of 5,641 participants were screened for clinical laboratory test results of serum CA199 levels over the past three years (2020-2023). This study included 2,464 healthy controls, 688 patients with type 2 diabetes, and 2,489 patients with 16 different types of cancer. Each type of cancer had more than 30 independent serum CA199 level test results. The serum CA199 levels were compared between cancer groups, type 2 diabetes patients, and healthy controls. Additionally, the CA199 levels of cancer patients were compared with those of patients with type 2 diabetes.
RESULTS: The serum CA199 levels of esophagus cancer, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, rectum cancer, prostate cancer, bladder cancer, liver cancer, gastric cancer, cervical cancer, colon cancer, lymphoma, thyroid cancer, intracranial tumors, and nasopharyngeal laryngeal cancer were found to be elevated compared to healthy controls (P < 0.01). In addition, the serum CA199 levels of patients with type 2 diabetes were also significantly elevated compared to healthy controls (P < 0.01). Moreover, the degree of elevation in serum CA199 levels in patients with type 2 diabetes was not significantly different from that observed in some types of cancer, such as esophagus cancer (P = 0.163), breast cancer (P = 0.927), prostate cancer (P = 1.000), bladder cancer (P = 0.406), Lymphoma (P = 0.975), thyroid cancer (P = 1.000), intracranial tumors (P = 0.161), nasopharyngeal and laryngeal cancer (P = 1.000).
CONCLUSIONS: Serum CA199 levels also increase in type 2 diabetes, and the magnitude of the increase is similar to that seen in some cancers.
METHODS: A total of 5,641 participants were screened for clinical laboratory test results of serum CA199 levels over the past three years (2020-2023). This study included 2,464 healthy controls, 688 patients with type 2 diabetes, and 2,489 patients with 16 different types of cancer. Each type of cancer had more than 30 independent serum CA199 level test results. The serum CA199 levels were compared between cancer groups, type 2 diabetes patients, and healthy controls. Additionally, the CA199 levels of cancer patients were compared with those of patients with type 2 diabetes.
RESULTS: The serum CA199 levels of esophagus cancer, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, rectum cancer, prostate cancer, bladder cancer, liver cancer, gastric cancer, cervical cancer, colon cancer, lymphoma, thyroid cancer, intracranial tumors, and nasopharyngeal laryngeal cancer were found to be elevated compared to healthy controls (P < 0.01). In addition, the serum CA199 levels of patients with type 2 diabetes were also significantly elevated compared to healthy controls (P < 0.01). Moreover, the degree of elevation in serum CA199 levels in patients with type 2 diabetes was not significantly different from that observed in some types of cancer, such as esophagus cancer (P = 0.163), breast cancer (P = 0.927), prostate cancer (P = 1.000), bladder cancer (P = 0.406), Lymphoma (P = 0.975), thyroid cancer (P = 1.000), intracranial tumors (P = 0.161), nasopharyngeal and laryngeal cancer (P = 1.000).
CONCLUSIONS: Serum CA199 levels also increase in type 2 diabetes, and the magnitude of the increase is similar to that seen in some cancers.
摘要：
目的：糖类抗原199（CA199）是标准的肿瘤标志物，最近的研究发现糖尿病患者的CA199水平升高。然而,没有系统的测量和比较糖尿病和癌症患者的血清CA199水平.这里,本研究对2型糖尿病和各种癌症患者血清CA199水平的变化进行了详细描述.
方法：在过去三年（2020-2023年）中，总共对5,641名参与者进行了血清CA199水平的临床实验室测试结果筛查。这项研究包括2,464名健康对照，688例2型糖尿病患者，和2,489名患者患有16种不同类型的癌症。每种类型的癌症都有30多个独立的血清CA199水平检测结果。比较癌症组之间的血清CA199水平，2型糖尿病患者,和健康的控制。此外,比较了癌症患者与2型糖尿病患者的CA199水平.
结果：食管癌患者血清CA199水平，肺癌,胰腺癌,卵巢癌,乳腺癌,直肠癌,前列腺癌,膀胱癌,肝癌,胃癌,宫颈癌,结肠癌,淋巴瘤甲状腺癌,颅内肿瘤,与健康对照组相比，鼻咽喉癌升高（P<0.01）。此外,2型糖尿病患者血清CA199水平也明显高于健康对照组(P<0.01)。此外，2型糖尿病患者血清CA199水平的升高程度与某些类型的癌症没有显着差异，如食管癌（P=0.163），乳腺癌（P=0.927），前列腺癌（P=1.000），膀胱癌（P=0.406），淋巴瘤（P=0.975），甲状腺癌（P=1.000），颅内肿瘤（P=0.161），鼻咽癌和喉癌(P=1.000)。
结论：2型糖尿病患者血清CA199水平也升高，增加的幅度与某些癌症相似。
方法：在过去三年（2020-2023年）中，总共对5,641名参与者进行了血清CA199水平的临床实验室测试结果筛查。这项研究包括2,464名健康对照，688例2型糖尿病患者，和2,489名患者患有16种不同类型的癌症。每种类型的癌症都有30多个独立的血清CA199水平检测结果。比较癌症组之间的血清CA199水平，2型糖尿病患者,和健康的控制。此外,比较了癌症患者与2型糖尿病患者的CA199水平.
结果：食管癌患者血清CA199水平，肺癌,胰腺癌,卵巢癌,乳腺癌,直肠癌,前列腺癌,膀胱癌,肝癌,胃癌,宫颈癌,结肠癌,淋巴瘤甲状腺癌,颅内肿瘤,与健康对照组相比，鼻咽喉癌升高（P<0.01）。此外,2型糖尿病患者血清CA199水平也明显高于健康对照组(P<0.01)。此外，2型糖尿病患者血清CA199水平的升高程度与某些类型的癌症没有显着差异，如食管癌（P=0.163），乳腺癌（P=0.927），前列腺癌（P=1.000），膀胱癌（P=0.406），淋巴瘤（P=0.975），甲状腺癌（P=1.000），颅内肿瘤（P=0.161），鼻咽癌和喉癌(P=1.000)。
结论：2型糖尿病患者血清CA199水平也升高，增加的幅度与某些癌症相似。
